抗疟药对类风湿关节炎患者使用生物制剂或Janus激酶抑制剂治疗安全性和持续性的影响
基于BiobadaBrasil多中心注册队列,纳入2009年1月至2019年10月起始bDMARD或JAKi的RA患者1316例(2335个疗程,6711患者年),评估抗疟药与治疗安全性的关联。抗疟药与严重不良事件(mIRR 0.49;95%CI 0.36,0.68;P<0.001)、总不良事件、严重感染及总肝脏不良事件风险降低相关,并与治疗疗程生存改善相关,心血管不良事件风险无显著增加。
要点
- 抗疟药与严重不良事件风险降低相关(mIRR 0.49;95%CI 0.36,0.68;P<0.001)
- 抗疟药与总不良事件、严重感染及总肝脏不良事件风险降低相关
- 抗疟药与治疗疗程生存改善相关(P=0.003),心血管不良事件风险无显著增加
核心结论
- 在接受bDMARD或JAKi治疗的RA患者中,合并使用抗疟药与严重及总不良事件发生率降低相关,并与治疗疗程生存期延长相关。
研究设计与样本
- BiobadaBrasil为多中心注册队列研究,纳入2009年1月至2019年10月起始首个bDMARD或JAKi的巴西风湿病患者。
- 本分析纳入RA患者1316例,共2335个疗程、6711患者年,其中抗疟药暴露1254.5患者年,随访至2019年11月19日。
- 主要结局为严重不良事件发生率,次要结局为总不良事件、系统特异性不良事件及治疗中断。
- 采用负二项回归结合广义估计方程估计多变量发病率比(mIRR),并采用frailty Cox比例风险模型进行统计分析。
主要发现
- 严重不良事件总发生率为9.2/100患者年。
- 抗疟药与严重不良事件风险降低相关(mIRR 0.49;95%CI 0.36,0.68;P<0.001)。
- 抗疟药与总不良事件风险降低相关(mIRR 0.68;95%CI 0.56,0.81;P<0.001)。
- 抗疟药与严重感染风险降低相关(mIRR 0.53;95%CI 0.34,0.84;P=0.007)。
- 抗疟药与总肝脏不良事件风险降低相关(mIRR 0.21;95%CI 0.05,0.85;P=0.028)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To test the association of use of antimalarials with the overall safety of treatment in RA patients receiving one or multiple courses of biologic (b)DMARDs or a Janus kinase inhibitor (JAKi). METHODS: BiobadaBrasil is a multicentric registry-based cohort study of Brazilian patients with rheumatic diseases starting their first bDMARD or JAKi. The present analysis includes RA patients recruited from January 2009 to October 2019, followed up over one or multiple (up to six) courses of treatment (latest date, 19 November 2019). The primary outcome was the incidence of serious adverse events (SAEs). Total and system-specific adverse events (AEs) and treatment interruption served as secondary outcomes. Negative binomial regression with generalized estimating equations (to estimate multivariate incidence rate ratios, mIRR) and frailty Cox proportional hazards models were used for statistical analyses. RESULTS: The number of patients enrolled was 1316 (2335 treatment courses, 6711 patient-years [PY]; 1254.5 PY on antimalarials). The overall incidence of SAEs was 9.2/100 PY. Antimalarials were associated with reduced risk of SAEs (mIRR: 0.49; 95% CI: 0.36, 0.68; P < 0.001), total AEs (0.68; 95% CI: 0.56, 0.81; P < 0.001), serious infections (0.53; 95% CI: 0.34, 0.84; P = 0.007) and total hepatic AEs (0.21; 95% CI: 0.05, 0.85; P = 0.028). Antimalarials were also related to better survival of treatment course (P = 0.003). There was no significant increase in the risk of cardiovascular AEs. CONCLUSION: Among RA patients on treatment with bDMARDs or JAKi, concomitant use of antimalarials was associated with reduced the incidence of serious and total AEs and with longer treatment course survival.
引用
- Bredemeier M, Duarte ÂL, Pinheiro MM, et al. The effect of antimalarials on the safety and persistence of treatment with biologic agents or Janus kinase inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2024. PMID: 37216912. doi:10.1093/rheumatology/kead232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。